What do the San Diego Comic-Con and multiple myeloma have in common? Does that sound like a very strange question? Am I still stuck…
Myeloma
Most myeloma patients taking Tecvayli (teclistamab-cqyv) were alive and free from disease progression two years after starting treatment, according to a new analysis…
I keep a ledger that no one else can see. It is not written in the notebook where I record medications and blood test…
A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For…
On some afternoons, while my mum and I are at the hospital, I notice how long it takes just to wait for our turn. Whether…
It’s the most wonderful time of the year! Some people have Christmas in July. Or the Fourth of July. I have nine days of fandom…
Dosing has begun in a Phase 3 clinical trial testing whether the antibody therapy Gamunex-C (immune globulin injection [human], 10% caprylate/chromatography purified) can help prevent…
The U.S. Food and Drug Administration (FDA) has set a date for next year by which it will decide whether or not to approve a…
Recent Posts
- Infection risk shifts over time with both CAR T and bispecific antibody therapy
- Building the quiet architecture of a caregiving day
- New CAR T-cell therapy shows promise in tough myeloma cases
- CAR T-cell therapy before surgery boosts glioblastoma control in mice
- Gynecologic Cancer Awareness Month urges education, action, and support